60 related articles for article (PubMed ID: 1489776)
1. [Myopathy and zidovudine].
Mateo O; Gato A; Ballesteros P; Benito L; Pontes MJ; Esquinas G
Enferm Infecc Microbiol Clin; 1992 Oct; 10(8):474-6. PubMed ID: 1489776
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS.
Peters BS; Winer J; Landon DN; Stotter A; Pinching AJ
Q J Med; 1993 Jan; 86(1):5-15. PubMed ID: 8438050
[TBL] [Abstract][Full Text] [Related]
3. Analysis of myopathy in a placebo-controlled zidovudine trial.
Simpson DM; Slasor P; Dafni U; Berger J; Fischl MA; Hall C
Muscle Nerve; 1997 Mar; 20(3):382-5. PubMed ID: 9052824
[No Abstract] [Full Text] [Related]
4. Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group.
Moore RD; Keruly J; Richman DD; Creagh-Kirk T; Chaisson RE
AIDS; 1992 Jul; 6(7):671-7. PubMed ID: 1503686
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial myopathy caused by long-term zidovudine therapy.
Dalakas MC; Illa I; Pezeshkpour GH; Laukaitis JP; Cohen B; Griffin JL
N Engl J Med; 1990 Apr; 322(16):1098-105. PubMed ID: 2320079
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy.
Grau JM; Masanés F; Pedrol E; Casademont J; Fernández-Solá J; Urbano-Márquez A
Ann Neurol; 1993 Aug; 34(2):206-11. PubMed ID: 8338345
[TBL] [Abstract][Full Text] [Related]
7. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
Phair JP; Abels RI; McNeill MV; Sullivan DJ
Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
[TBL] [Abstract][Full Text] [Related]
9. Exacerbation of HIV-associated myopathy by zidovudine.
Berger JR; Shebert R; Gregorios JB
AIDS; 1991 Feb; 5(2):229-30. PubMed ID: 2031699
[No Abstract] [Full Text] [Related]
10. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction.
Mhiri C; Baudrimont M; Bonne G; Geny C; Degoul F; Marsac C; Roullet E; Gherardi R
Ann Neurol; 1991 Jun; 29(6):606-14. PubMed ID: 1892364
[TBL] [Abstract][Full Text] [Related]
11. Myopathy in human immunodeficiency virus-infected children receiving long-term zidovudine therapy.
Walter EB; Drucker RP; McKinney RE; Wilfert CM
J Pediatr; 1991 Jul; 119(1 Pt 1):152-5. PubMed ID: 1906098
[No Abstract] [Full Text] [Related]
12. Muscle symptoms associated with statins: a series of twenty patients.
Soininen K; Niemi M; Kilkki E; Strandberg T; Kivistö KT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):51-4. PubMed ID: 16433891
[TBL] [Abstract][Full Text] [Related]
13. [Comparative study of various biological markers in HIV 1 infection].
Serra JE; Pombo V; Côrte-Real R; da Cunha S; Meliço-Silvestre A
Acta Med Port; 1993 Jan; 6(1):5-9. PubMed ID: 8097351
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy.
Chariot P; Monnet I; Gherardi R
Ann Neurol; 1993 Oct; 34(4):561-5. PubMed ID: 8215243
[TBL] [Abstract][Full Text] [Related]
15. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
[TBL] [Abstract][Full Text] [Related]
16. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
[TBL] [Abstract][Full Text] [Related]
17. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of AIDS patients with zidovudine].
Buijs L; Pietersz RN; van den Berg-Wolf MG; Reesink HW; ten Veen JH
Ned Tijdschr Geneeskd; 1990 Jan; 134(2):71-5. PubMed ID: 2296325
[TBL] [Abstract][Full Text] [Related]
19. Blunted humoral response to influenza vaccination in patients exposed to zidovudine plus trimethoprim-sulfamethoxazole.
Feola DJ; Garvy BA; Rapp RP; Thornton AC
Pharmacotherapy; 2007 Jul; 27(7):937-47. PubMed ID: 17594199
[TBL] [Abstract][Full Text] [Related]
20. Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine.
Manji H; Harrison MJ; Round JM; Jones DA; Connolly S; Fowler CJ; Williams I; Weller IV
J Neurol; 1993 Sep; 240(8):479-88. PubMed ID: 8263554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
